Establishing secure connection…Loading editor…Preparing document…

Informed Consent for Isotretinoin Treatment

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

Patient Information/Informed Consent (for all patients)

To be completed by patient (and parent or guardian if patient is under age 18) and signed by the doctor.

Read each item below and initial in the space provided if you understand each item and agree to follow your doctor’s instructions. A parent or guardian of a patient under age 18 must also read and understand each item before signing the agreement.

Do not sign this agreement and do not take isotretinoin if there is anything that you do not understand about all the information you have received about using isotretinoin.

1. I, understand that isotretinoin is a medicine used to treat severe nodular acne that cannot be cleared up by any other acne treatments, including antibiotics. In severe nodular acne, many red, swollen, tender lumps form in the skin. If untreated, severe nodular acne can lead to permanent scars.

Initials:

2. My doctor has told me about my choices for treating my acne.

Initials:

3. I understand that there are serious side effects that may happen while I am taking isotretinoin. These have been explained to me. These side effects include serious birth defects in babies of pregnant patients. [Note: There is a second Patient Information/Informed Consent About Birth Defects (for female patients who can get pregnant)].

Initials:

4. I understand that some patients, while taking isotretinoin or soon after stopping isotretinoin, have become depressed or developed other serious mental problems. Symptoms of depression include sad, “anxious” or empty mood, irritability, acting on dangerous impulses, anger, loss of pleasure or interest in social or sports activities, sleeping too much or too little, changes in weight or appetite, school or work performance going down, or trouble concentrating. Some patients taking isotretinoin have had thoughts about hurting themselves or putting an end to their own lives (suicidal thoughts). Some people tried to end their own lives. And some people have ended their own lives. There were reports that some of these people did not appear depressed. There have been reports of patients on isotretinoin becoming aggressive or violent. No one knows if isotretinoin caused these behaviors or if they would have happened even if the person did not take isotretinoin. Some people have had other signs of depression while taking isotretinoin (see #7).

Initials:

5. Before I start taking isotretinoin, I agree to tell my doctor if I have ever had symptoms of depression (see #7), been psychotic, attempted suicide, had any other mental problems, or take medicine for any of these problems. Being psychotic means having a loss of contact with reality, such as hearing voices or seeing things that are not there.

Initials:

6. Before I start taking isotretinoin, I agree to tell my doctor if, to the best of my knowledge, anyone in my family has ever had symptoms of depression, been psychotic, attempted suicide, or had any other serious mental problems.

Initials:

7. Once I start taking isotretinoin, I agree to stop using isotretinoin and tell my doctor right away if any of the following signs and symptoms of depression or psychosis happen. I:

Start to feel sad or have crying spells

Lose interest in activities I once enjoyed

Sleep too much or have trouble sleeping

Become more irritable, angry, or aggressive than usual (for example, temper outbursts, thoughts of violence)

Have a change in my appetite or body weight

Have trouble concentrating

Withdraw from my friends or family

Feel like I have no energy

Have feelings of worthlessness or guilt

Start having thoughts about hurting myself or taking my own life (suicidal thoughts)

Start acting on dangerous impulses

Start seeing or hearing things that are not real

Initials:

8. I agree to return to see my doctor every month I take isotretinoin to get a new prescription for isotretinoin, to check my progress, and to check for signs of side effects.

Initials:

9. Isotretinoin will be prescribed just for me — I will not share isotretinoin with other people because it may cause serious side effects, including birth defects.

Initials:

10. I will not give blood while taking isotretinoin or for 1 month after I stop taking isotretinoin. I understand that if someone who is pregnant gets my donated blood, her baby may be exposed to isotretinoin and may be born with serious birth defects.

Initials:

11. I have read The iPLEDGE Program Patient Introductory Brochure and other materials my provider gave me containing important safety information about isotretinoin. I understand all the information I received.

Initials:

12. My doctor and I have decided I should take isotretinoin. I understand that I must be qualified in the iPLEDGE program to have my prescription filled each month. I understand that I can stop taking isotretinoin at any time. I agree to tell my doctor if I stop taking isotretinoin.

Initials:

I now allow my doctor to begin my treatment with isotretinoin.

Patient Signature:

Date:

Parent/Guardian Signature (if under age 18):

Date:

Patient Name (print)

Patient Address

Telephone

I have:

• fully explained to the patient, , the nature and purpose of isotretinoin treatment, including its benefits and risks

• given the patient the appropriate educational materials, The iPLEDGE Program Patient Introductory Brochure and asked the patient if he/she has any questions regarding his/her treatment with isotretinoin

• answered those questions to the best of my ability

Doctor Signature:

Date:

PLACE THE ORIGINAL SIGNED DOCUMENTS IN THE PATIENT’S MEDICAL RECORD.

PLEASE PROVIDE A COPY TO THE PATIENT.

www.ipledgeprogram.com 1-866-495-0654

iPLEDGE–Committed to Pregnancy Prevention

P.O. Box 29094

Phoenix, AZ 85038

Enter text✕

What the Informed Consent for Isotretinoin Treatment Is

The Informed Consent for Isotretinoin Treatment documents a patient's understanding of the medication's intended benefits, known risks, monitoring requirements, and mandatory safety measures before beginning therapy. Isotretinoin is a potent oral retinoid with significant teratogenic risk; the form typically explains side effects, alternative options, pregnancy prevention obligations, required laboratory monitoring, and expected follow-up visits. The consent creates a written record that the prescriber discussed risks and that the patient agreed to adhere to monitoring and prevention protocols, which supports clinical decision-making and regulatory compliance.

Why a Clear Consent Matters in Isotretinoin Care

A signed consent clarifies risks and responsibilities, protects patient autonomy, and documents informed choice before starting treatment.

Why a Clear Consent Matters in Isotretinoin Care

Who Completes and Signs This Consent

The form is completed by the prescribing clinician with the patient, and signed by the patient or authorized representative.

  • Prescribing clinicians and staff complete counseling and enter monitoring instructions.
  • Adult patients sign to acknowledge risks, pregnancy prevention, and monitoring obligations.
  • Parents or guardians sign for minors and confirm understanding of required steps.

Parents or legal guardians must sign for minors where state law requires parental consent; clinicians remain responsible for documenting counseling and eligibility checks.

Essential Elements Every Professional Consent Should Include

A clinical consent form should be concise but comprehensive, covering medication details, key risks, pregnancy prevention, monitoring, alternative treatments, and contact instructions for adverse events.

Medication Info

Drug name, usual dosing range, and typical course length; note dose adjustments and duration expectations for therapeutic effect and side-effect monitoring.

Major Risks

Clear explanation of teratogenicity, psychiatric and dermatologic risks, lab abnormalities, and other common or serious adverse effects that patients should monitor and report promptly.

Pregnancy Prevention

Explicit requirements for pregnancy testing, contraception, and timing relative to therapy start and discontinuation, aligned with REMS or clinic protocol.

Monitoring Plan

Schedule for baseline and periodic labs, pregnancy tests, follow-up visits, and who reviews results; include frequency and responsible parties.

Alternatives

Summary of other therapeutic options, expected benefits and risks compared with isotretinoin, and acknowledgment that alternatives were discussed.

Emergency Instructions

When and how to seek urgent care for severe side effects, suspected pregnancy, or mood changes, plus clinic contact hours and escalation steps.

Step-by-Step: Filling Out the Consent

Follow these sequential actions to complete and document informed consent accurately and consistently.

  • 01
    Review Risks: Clinician explains major risks, including teratogenicity and monitoring needs.
  • 02
    Document Counseling: Record date, time, and key counseling points in the chart and on the form.
  • 03
    Confirm Tests: Obtain and attach baseline labs and pregnancy test results as required.
  • 04
    Signed Acknowledgement: Patient (or guardian) signs and dates the form; store in the medical record.

Typical Online Consent Workflow

Digital workflows reduce errors and centralize monitoring; a standard process improves compliance and audit readiness.

  • Upload Document: Upload the consent PDF or template into the e-sign platform.
  • Place Fields: Add signature, initials, date, and upload fields for lab results or pregnancy tests.
  • Send to Signer: Dispatch the signing request by secure email or SMS link with authentication.
  • Capture Audit Trail: Platform logs signer identity, timestamps, and IP address for the record.

Recommended Digital Workflow Settings

Configure authentication, consent disclosures, and file upload requirements to match clinical and regulatory needs.

Field Configuration
Authentication SMS code or email link for signer verification
Consent Disclosure Include ESIGN consumer disclosure for patient consent
Pregnancy Test Upload Require scanned result or lab file before finalizing
Automated Reminders Set SMS/email reminders for pending signatures and tests

Technical and Compliance Considerations for eSubmission

Choose a platform that supports secure uploads, audit trails, and health-data protections appropriate for medical records.

  • Accepted Formats: PDF, DOCX, and scanned images
  • Security Standards: TLS in transit and AES-256 at rest
  • Integrations: EHR and cloud storage connectors

Key Timing and Monitoring Requirements

Track baseline testing, follow-up visits, and pregnancy testing cadence to meet clinical and program obligations.

Baseline Evaluation:

Obtain baseline labs and pregnancy test before the first dose

Monthly Follow-up:

Clinician review and pregnancy test typically performed monthly while on therapy

iPLEDGE Enrollment:

Complete any registry enrollment before dispensing medication

Post-Discontinuation:

Advise contraception and pregnancy testing for recommended interval after stopping

Recordkeeping:

Document visits and test results promptly in the medical record

Common Errors to Avoid When Preparing Consent

  • Failing to document counseling content precisely, which can lead to incomplete records and regulatory scrutiny.
  • Omitting or misdating pregnancy test results, risking noncompliance with safety program requirements and patient safety.
  • Allowing unsigned or partially completed forms to remain active in the chart, creating ambiguity about informed assent.
  • Not verifying signer identity or guardian authority for minors, leading to invalid or contestable consents.

Security and Privacy Elements to Include

HIPAA Safeguards: Apply access controls and audit logging
Encryption: TLS for transit, AES-256 for storage
Business Associate: BAA required for cloud e-sign vendors
Access Controls: Role-based permissions for staff
Retention Policy: Store according to regulatory timelines
Audit Trail: Time-stamped signer actions and IP

Consequences of Incomplete or Incorrect Consent

Patient Harm: Increased clinical risk from missed monitoring
Legal Liability: Malpractice claims for inadequate consent
Regulatory Noncompliance: Violations of REMS or state rules
Program Penalties: Restrictions on dispensing or registry sanctions
Billing Rejection: Payer denials without proper documentation
Record Challenges: Difficulty defending care decisions later

Sample eSignature Vendor Comparison

Basic pricing and capability differences among common e-signature vendors. signNow is shown first; verify plan details with each vendor before purchase.

signNow DocuSign Adobe Sign PandaDoc HelloSign
Starting Price $8/user/mo $15/user/mo $14/user/mo $19/user/mo $15/user/mo
Free Trial 7-day free trial, no card No No Yes, limited Yes, limited
Bulk Send Yes Yes Yes Yes No
Audit Trail Yes Yes Yes Yes Yes
HIPAA Compliant Yes (BAA) Yes Yes No No

Frequently Asked Questions

Answers to common questions about legal validity, signature methods, minors, and recordkeeping for isotretinoin consent forms.


Need help? Contact support

be ready to get more
Join over 28 million airSlate SignNow users